Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis.